ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 1376

Diagnostic Performance of 7 Different Anti-Cyclic Citrullinated Peptide Antibody and 6 Rheumatoid Factor Assays in a Primary Diagnostic, Consecutive Rheumatological Population in a Secondary Care Hospital

Lieve Van Hoovels1, Julie Jacobs1, Bert Vander Cruyssen2, Stefanie Van den Bremt1, Patrick Verschueren3 and Xavier Bossuyt4, 1Laboratory medicine, OLV Hospital, Aalst, Belgium, 2Rheumatology, OLV hospital, Aalst, Belgium, 3Division of Rheumatology, University Hospital Leuven, Leuven, Belgium, 4Laboratory medicine, University Hospital Leuven, Leuven, Belgium

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: ACPA, Classification criteria and rheumatoid arthritis (RA), Rheumatoid Factor

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 6, 2017

Session Title: Rheumatoid Arthritis – Clinical Aspects Poster II: Pathophysiology, Autoantibodies, and Disease Activity Measures

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose:

The clinical diagnosis of rheumatoid arthritis (RA) remains a challenge, making serological markers most interesting. The 2010 ACR/EULAR classification criteria for RA take into account two serological markers: anti-cyclic citrullinated peptide (ACPA) and rheumatoid factor (RF).

The objective of this study is to evaluate the diagnostic performance of 6 RF and 7 ACPA assays in a secondary care hospital

Methods:

From January 2014 to June 2015, all unique patients who for the first time underwent laboratory testing for a rheumatologic disease at the OLV hospital Aalst were included. Review of the medical records was done and the diagnosis was registered and reviewed by the consulting rheumatologist. Patients were categorized into three groups: RA, rheumatologic disease control group (RDCG) and disease control group (DCG). For all RA patients the fulfillment of the ACR classification criteria (1987 and 2010) was checked. Six commercial RF assays (Zenit, Phadia, Inova, Roche, Abbott, Euroimmun (EI)) and 7 commercial ACPA assays (Zenit, Phadia, BIOFlash Inova (BF), Roche, Abbott, EuroDiagnostica (ED), EI) were tested and diagnostic performance (sensitivity, specificity, receiver operating characteristics (ROC) curve analysis, likelihood ratio (LR)) evaluated.

Results:

We included 594 patients: 44 (7,4%) RA, 247 (41,6%) RDGC and 225 (37,9%) DCG. For 78 (13,1%) the diagnosis remained undifferentiated. Most of the included RA patients fulfilled the ACR classification criteria (94,3% 1987; 78.56% 2010).

Sensitivities for RF range from 35,7-44,3% and for ACPA from 35,7-41,4% (Table 1), lower than normally described. Demographic patient features, like older patients, could be partly responsible for this low RF/ACPA positivity. The low false positive reactivities in the control patient cohorts are also quite remarkable for RF, as RF is historically known as a more aspecific serological RA marker. Since the control group consists of a primary diagnostic, consecutive rheumatological population, they represent the real life setting in this secondary care hospital, reflecting the true diagnostic usefulness of the RF/ACPA analyses. A negative serological test result will not exclude RA. For RF the importance of a weak positive result (1-3 times cut-off value) depends on the assay used. For ACPA a weak positive result is of diagnostic importance. Strong positive RF or ACPA results can aid in the diagnosis of RA as they have a high LR for RA (>10 for all assays), except for two RF assays (from Inova and Euroimmun).

Conclusion:

The aid of the serological reactivities in the diagnosis of RA is dependent on the choice of the RF (especially) or ACPA assay used due to the lack of harmonization. Demographic features of the patient population and the possible low serological positive RA pretest probability will also influence the usefulness of these serological tests.


Disclosure: L. Van Hoovels, None; J. Jacobs, None; B. Vander Cruyssen, None; S. Van den Bremt, None; P. Verschueren, AbbVie, Bristol-Myers Squibb, Eli Lilly, Merck Sharpe & Dohme, Pfizer, Roche, Sanofi, and UCB, 5,Pfizer chair for early RA management at KU Leuven, 6; X. Bossuyt, None.

To cite this abstract in AMA style:

Van Hoovels L, Jacobs J, Vander Cruyssen B, Van den Bremt S, Verschueren P, Bossuyt X. Diagnostic Performance of 7 Different Anti-Cyclic Citrullinated Peptide Antibody and 6 Rheumatoid Factor Assays in a Primary Diagnostic, Consecutive Rheumatological Population in a Secondary Care Hospital [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/diagnostic-performance-of-7-different-anti-cyclic-citrullinated-peptide-antibody-and-6-rheumatoid-factor-assays-in-a-primary-diagnostic-consecutive-rheumatological-population-in-a-secondary-care-hosp/. Accessed January 31, 2023.
  • Tweet
  • Email
  • Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/diagnostic-performance-of-7-different-anti-cyclic-citrullinated-peptide-antibody-and-6-rheumatoid-factor-assays-in-a-primary-diagnostic-consecutive-rheumatological-population-in-a-secondary-care-hosp/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences